Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2165/00003495-200868130-00009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Superiority of low-dose benzbromarone to low-dose febuxostat in gout patients with renal uric acid underexcretion: comment on the article by Yan et al.
Arthritis Rheumatol
September 2023
Department of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan.
Effects of Uric Acid-Lowering Therapy on the Kidney (HTR-2023-0096.R2).
Hypertens Res
June 2023
Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Febuxostat, a potential drug in the secondary prevention of cardiovascular disease with hyperuricemia.
Int J Cardiol
January 2023
The First Affiliated Hospital of University of South China, Department of Function, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, PR China. Electronic address:
Febuxostat Use and Safety in Patients With Hyperuricemia.
J Rheumatol
October 2022
Department of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan.
Reply to comment on "Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta-analysis".
Clin Cardiol
July 2022
Department of Comprehensive Surgery, General Hospital of Chinese People's Liberation Army & National Clinical Research Center for Geriatric Disease, Beijing, China.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!